yes but his last straw argument is now that IA showed that endpoints needed to be changed in order to get efficiency on new endpoints so they changed the endpoints, which will not be permitted by the FDA. If that was the reason, then still its absolute BS since the FDA permits endpoint changes ALL the time even if the reason is on blinded IA. Ex last hope is FDA will not approve the trial because the bases on which the endpoints were changed are corrupt. Complete nonsense.
There are many good articles on how to change endpoints in a medical trials.
Market Data 
Markets 
